Pacira Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PACIRA PHARMS INC, and when can generic versions of PACIRA PHARMS INC drugs launch?
PACIRA PHARMS INC has four approved drugs.
There are eighteen US patents protecting PACIRA PHARMS INC drugs.
There are sixty patent family members on PACIRA PHARMS INC drugs in twenty-three countries and eighteen supplementary protection certificates in eight countries.
Summary for Pacira Pharms Inc
| International Patents: | 60 |
| US Patents: | 18 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Pacira Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-001 | Oct 28, 2011 | AP | RX | Yes | Yes | 11,278,494 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-001 | Oct 28, 2011 | AP | RX | Yes | Yes | 12,156,940 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-002 | Oct 28, 2011 | AP | RX | Yes | Yes | 11,819,574 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-002 | Oct 28, 2011 | AP | RX | Yes | Yes | 11,426,348 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Pacira Pharms Inc | ZILRETTA | triamcinolone acetonide | FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | 208845-001 | Oct 6, 2017 | RX | Yes | Yes | 9,555,048 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-001 | Oct 28, 2011 | AP | RX | Yes | Yes | 11,311,486 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-001 | Oct 28, 2011 | AP | RX | Yes | Yes | 11,357,727 | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pacira Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | 5,723,147 | ⤷ Subscribe |
| Pacira Pharms Inc | DEPODUR | morphine sulfate | INJECTABLE, LIPOSOMAL;EPIDURAL | 021671-001 | May 18, 2004 | 5,931,809 | ⤷ Subscribe |
| Pacira Pharms Inc | DEPODUR | morphine sulfate | INJECTABLE, LIPOSOMAL;EPIDURAL | 021671-001 | May 18, 2004 | 6,241,999 | ⤷ Subscribe |
| Pacira Pharms Inc | DEPODUR | morphine sulfate | INJECTABLE, LIPOSOMAL;EPIDURAL | 021671-002 | May 18, 2004 | 6,071,534 | ⤷ Subscribe |
| Pacira Pharms Inc | DEPODUR | morphine sulfate | INJECTABLE, LIPOSOMAL;EPIDURAL | 021671-001 | May 18, 2004 | 5,723,147 | ⤷ Subscribe |
| Pacira Pharms Inc | DEPODUR | morphine sulfate | INJECTABLE, LIPOSOMAL;EPIDURAL | 021671-002 | May 18, 2004 | 6,241,999 | ⤷ Subscribe |
| Pacira Pharms Inc | EXPAREL | bupivacaine | INJECTABLE, LIPOSOMAL;INJECTION | 022496-002 | Oct 28, 2011 | 6,132,766 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Pacira Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2018100114 | ⤷ Subscribe |
| Australia | 2017268620 | ⤷ Subscribe |
| Canada | 2956556 | ⤷ Subscribe |
| Spain | 2642312 | ⤷ Subscribe |
| China | 107669640 | ⤷ Subscribe |
| Taiwan | I548412 | ⤷ Subscribe |
| South Korea | 20130093101 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pacira Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2768484 | SPC/GB19/067 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308(FOR NI) 20180827; UK PLGB 31626/0004 20180827 |
| 1744764 | 300960 | Netherlands | ⤷ Subscribe | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 3300601 | LUC00271 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
| 3300601 | 2022C/528 | Belgium | ⤷ Subscribe | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
| 2768484 | 2019/054 | Ireland | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
| 1744764 | 2018/042 | Ireland | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| 1744764 | SPC/GB18/045 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308/001-003 20180827; UK PLGB 31626/0004 20180827 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
